Top-Rated StocksTop-RatedNASDAQ:IRON Disc Medicine (IRON) Stock Price, News & Analysis $65.01 +1.20 (+1.88%) (As of 12/24/2024 03:03 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Disc Medicine Stock (NASDAQ:IRON) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Disc Medicine alerts:Sign Up Key Stats Today's Range$62.94▼$66.1650-Day Range$44.82▼$67.4752-Week Range$25.60▼$77.60Volume70,910 shsAverage Volume345,398 shsMarket Capitalization$1.93 billionP/E RatioN/ADividend YieldN/APrice Target$87.50Consensus RatingBuy Company OverviewDisc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.Read More… Disc Medicine Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks68th Percentile Overall ScoreIRON MarketRank™: Disc Medicine scored higher than 68% of companies evaluated by MarketBeat, and ranked 332nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingDisc Medicine has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDisc Medicine has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Disc Medicine's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Disc Medicine are expected to decrease in the coming year, from ($4.05) to ($5.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Disc Medicine is -16.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Disc Medicine is -16.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDisc Medicine has a P/B Ratio of 4.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.44% of the float of Disc Medicine has been sold short.Short Interest Ratio / Days to CoverDisc Medicine has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Disc Medicine has recently decreased by 0.61%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDisc Medicine does not currently pay a dividend.Dividend GrowthDisc Medicine does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.44% of the float of Disc Medicine has been sold short.Short Interest Ratio / Days to CoverDisc Medicine has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Disc Medicine has recently decreased by 0.61%, indicating that investor sentiment is improving. News and Social Media3.2 / 5News Sentiment0.84 News SentimentDisc Medicine has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Disc Medicine this week, compared to 5 articles on an average week.Search Interest16 people have searched for IRON on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Disc Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,883,150.00 in company stock.Percentage Held by InsidersOnly 4.24% of the stock of Disc Medicine is held by insiders.Percentage Held by Institutions83.70% of the stock of Disc Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Disc Medicine's insider trading history. Receive IRON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Disc Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address IRON Stock News HeadlinesJohn D. Quisel Sells 12,791 Shares of Disc Medicine, Inc. (NASDAQ:IRON) StockDecember 19, 2024 | insidertrades.comDisc Medicine, Inc. (NASDAQ:IRON) Director William Richard White Sells 1,957 SharesDecember 5, 2024 | insidertrades.comWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.December 25, 2024 | Behind the Markets (Ad)Disc Medicine, Inc. (NASDAQ:IRON) Insider William Jacob Savage Sells 14,183 SharesNovember 27, 2024 | insidertrades.comDisc Medicine (NASDAQ:IRON) Shares Down 3% - What's Next?December 22 at 4:07 AM | americanbankingnews.comPromising Pipeline Developments Bolster Buy Rating for Disc MedicineDecember 11, 2024 | markets.businessinsider.comDisc Medicine price target raised to $90 from $79 at StifelDecember 11, 2024 | markets.businessinsider.comScotiabank Remains a Buy on Disc Medicine (IRON)December 10, 2024 | markets.businessinsider.comSee More Headlines IRON Stock Analysis - Frequently Asked Questions How have IRON shares performed this year? Disc Medicine's stock was trading at $57.76 at the start of the year. Since then, IRON shares have increased by 12.6% and is now trading at $65.01. View the best growth stocks for 2024 here. How were Disc Medicine's earnings last quarter? Disc Medicine, Inc. (NASDAQ:IRON) posted its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.04) by $0.15. Who are Disc Medicine's major shareholders? Disc Medicine's top institutional investors include Wellington Management Group LLP (6.19%), State Street Corp (2.78%), Point72 Asset Management L.P. (2.54%) and Janus Henderson Group PLC (2.52%). Insiders that own company stock include Venture Fund X LP Atlas, Holdings A/S Novo, Orbimed Advisors Llc, John D Quisel, William Jacob Savage, Brian Richard Macdonald, Joanne Bryce, Rahul Khara and Mona Ashiya. View institutional ownership trends. How do I buy shares of Disc Medicine? Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Disc Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Disc Medicine investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Arista Networks (ANET), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Jabil (JBL). Company Calendar Last Earnings11/12/2024Today12/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IRON CUSIPN/A CIK1816736 Webwww.discmedicine.com Phone617-401-4400FaxN/AEmployees78Year FoundedN/APrice Target and Rating Average Stock Price Target$87.50 High Stock Price Target$118.00 Low Stock Price Target$70.00 Potential Upside/Downside+34.6%Consensus RatingBuy Rating Score (0-4)3.10 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($3.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,430,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-25.24% Return on Assets-23.96% Debt Debt-to-Equity RatioN/A Current Ratio19.36 Quick Ratio19.36 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$14.17 per share Price / Book4.59Miscellaneous Outstanding Shares29,758,000Free Float28,496,000Market Cap$1.93 billion OptionableNot Optionable Beta0.76 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:IRON) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Disc Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Disc Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.